Natco Pharma launches generic blood cancer drug in India

PTI New Delhi | Updated on January 11, 2018


Natco Pharma has launched a generic version of pomalidomide capsules, used in the treatment of a type of blood cancer, in India.

“Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy,” Natco said in a BSE filing today.

Myeloma is a type of blood cancer.

Natco has launched pomalidomide capsules in strengths of 1 mg, 2 mg and 4 mg in India.

Pomalidomide is sold by Celgene Inc., in the US, under the brand name POMALYST.

Natco Pharma said it will market generic pomalidomide capsules under its brand name POMALID in India.

Natco has priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP of Rs 5,000, Rs 10,000 and Rs 20,000 respectively, for a monthly pack of 21 capsules, the company said.

“We believe, this is approximately 98 per cent discount of price from what it is sold at in the USA to patients, as per secondary market data researched,” the company added.

Shares of Natco Pharma were trading 1.52 per cent up at Rs 909 on the BSE.

Published on May 10, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like